Legend Biotech Announces Appointment of Dr. Patrick Casey to the Board of Directors
December 03 2020 - 7:00AM
Business Wire
Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a
global clinical-stage biopharmaceutical company engaged in the
discovery and development of novel cell therapies for oncology and
other indications, announced today that it has appointed Dr.
Patrick Casey as an independent director to Legend Biotech’s Board
of Directors. Dr. Casey will serve as a Class II director.
“We are delighted to have Dr. Casey join our Board of
Directors,” said Sally Wang, Chairwoman of Legend Biotech. “Dr.
Casey brings extraordinary scientific expertise and research
leadership experience that greatly enhances our Board. I am
confident that Legend Biotech will greatly benefit from his
participation as we continue to execute on our pipeline development
strategy and objective to bring innovative and impactful cell
therapies toward potential registration and commercialization.”
Patrick Casey, PhD, is the Senior Vice Dean of Research at the
Duke-NUS Medical School and a James B. Duke Professor of
Pharmacology and Cancer Biology at Duke University. Dr. Casey
joined Duke University Medical Center as an Assistant Professor of
Molecular Cancer Biology and Biochemistry in 1990. In 2005, Dr.
Casey relocated to Singapore to spearhead the development of the
Signature Research Programmes at Duke-NUS, where he currently
oversees the administration and strategic planning of these
programmes, and mentoring of faculty and trainees. He was also the
founding Director of the Duke Center for Chemical Biology—an
organization of Duke scientists dedicated to research and training
in the application of fundamental chemical principles to the study
of biology and the basis of disease and therapies. A recognized
authority in the fields of lipid modifications of proteins and in G
protein signaling, Dr. Casey has received several awards for his
work, including the Established Investigator Award from the
American Heart Association in 1992 and the Amgen Award from the
American Society of Biochemistry and Molecular Biology in 2000. He
was elected a Fellow of the American Association for the
Advancement of Science in 2012. Dr. Casey serves on advisory panels
for Agency for Science, Technology and Research (A*STAR), National
Research Foundation (NRF) and National Medical Research Council
(NMRC). Dr. Casey received his PhD in Biochemistry from the
Brandeis University in 1986 and did postdoctoral work at the
University of Texas Southwestern Medical Center in Dallas.
About Legend Biotech
Legend Biotech is a global clinical-stage biopharmaceutical
company engaged in the discovery and development of novel cell
therapies for oncology and other indications. Our team of over 800
employees across the United States, China and Europe, along with
our differentiated technology, global development, and
manufacturing strategies and expertise, provide us with the strong
potential to discover, develop, and manufacture cutting edge cell
therapies for patients in need.
We are engaged in a strategic collaboration to develop and
commercialize our lead product candidate, ciltacabtagene
autoleucel, an investigational BCMA-targeted CAR-T cell therapy for
patients living with multiple myeloma. This candidate is currently
being studied in registrational clinical trials. To learn more
about Legend Biotech, visit us on LinkedIn, or on Twitter
@LegendBiotech or at www.legendbiotech.com.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
“forward-looking statements” within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements relating to statements relating
to
Legend Biotech’s strategic development and objectives and the
potential contributions of its new board member. The words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including the factors discussed in the “Risk Factors”
section of the prospectus filed with the Securities and Exchange
Commission on June 8, 2020. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and Legend Biotech specifically disclaims any obligation to update
any forward-looking statement, whether as a result of new
information, future events or otherwise. Readers should not rely
upon the information on this page as current or accurate after its
publication date.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201203005242/en/
For Investor Relations inquiries, please contact: Jessie
Yeung, Head of Corporate Finance and Investor Relations, Legend
Biotech USA Inc. jessie.yeung@legendbiotech.com or
investor@legendbiotech.com
Surabhi Verma, Manager of Investor Relations and Corporate
Communications, Legend Biotech USA Inc.
Surabhi.Verma@legendbiotech.com or media@legendbiotech.com
For Medical Affairs inquiries, please contact: Tonia
Nesheiwat, Executive Director, Medical Affairs, Legend Biotech USA
Inc. tonia.nesheiwat@legendbiotech.com or
medicalinformation@legendbiotech.com
Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Jul 2023 to Jul 2024